318 related articles for article (PubMed ID: 31707366)
1. Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-β Levels.
Valech N; Sánchez-Benavides G; Tort-Merino A; Coll-Padrós N; Olives J; León M; Falcon C; Molinuevo JL; Rami L
J Alzheimers Dis; 2019; 72(4):1287-1302. PubMed ID: 31707366
[TBL] [Abstract][Full Text] [Related]
2. Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging.
Valech N; Mollica MA; Olives J; Tort A; Fortea J; Lleo A; Belén SS; Molinuevo JL; Rami L
J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S87-98. PubMed ID: 26445275
[TBL] [Abstract][Full Text] [Related]
3. Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging.
Valech N; Tort-Merino A; Coll-Padrós N; Olives J; León M; Rami L; Molinuevo JL
J Alzheimers Dis; 2018; 61(2):689-703. PubMed ID: 29254090
[TBL] [Abstract][Full Text] [Related]
4. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
[TBL] [Abstract][Full Text] [Related]
5. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
6. 18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer's Disease Biomarkers in Subjective Cognitive Decline Population.
Zhao Z; Wang J; Wang Y; Liu X; He K; Guo Q; Xie F; Huang Q; Li Z
J Alzheimers Dis; 2023; 93(2):585-594. PubMed ID: 37066915
[TBL] [Abstract][Full Text] [Related]
7. Subjective cognitive decline-related worries modulate the relationship between global amyloid load and gray matter volume in preclinical Alzheimer's disease.
Wang X; Wang M; Wang X; Zhou F; Jiang J; Liu H; Han Y
Brain Imaging Behav; 2022 Jun; 16(3):1088-1097. PubMed ID: 34743296
[TBL] [Abstract][Full Text] [Related]
8. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.
Kimura A; Yoshikura N; Hayashi Y; Inuzuka T
J Alzheimers Dis; 2018; 61(2):581-588. PubMed ID: 29171996
[TBL] [Abstract][Full Text] [Related]
10. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies.
Hu X; Teunissen CE; Spottke A; Heneka MT; Düzel E; Peters O; Li S; Priller J; Buerger K; Teipel S; Laske C; Verfaillie SCJ; Barkhof F; Coll-Padrós N; Rami L; Molinuevo JL; van der Flier WM; Jessen F
Alzheimers Dement; 2019 Feb; 15(2):185-193. PubMed ID: 30321506
[TBL] [Abstract][Full Text] [Related]
11. Structural neuroimaging changes associated with subjective cognitive decline from a clinical sample.
Riverol M; Ríos-Rivera MM; Imaz-Aguayo L; Solis-Barquero SM; Arrondo C; Montoya-Murillo G; Villino-Rodríguez R; García-Eulate R; Domínguez P; Fernández-Seara MA
Neuroimage Clin; 2024; 42():103615. PubMed ID: 38749146
[TBL] [Abstract][Full Text] [Related]
12. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.
Miebach L; Wolfsgruber S; Polcher A; Peters O; Menne F; Luther K; Incesoy E; Priller J; Spruth E; Altenstein S; Buerger K; Catak C; Janowitz D; Perneczky R; Utecht J; Laske C; Buchmann M; Schneider A; Fliessbach K; Kalbhen P; Heneka MT; Brosseron F; Spottke A; Roy N; Teipel SJ; Kilimann I; Wiltfang J; Bartels C; Düzel E; Dobisch L; Metzger C; Meiberth D; Ramirez A; Jessen F; Wagner M
Alzheimers Res Ther; 2019 Jul; 11(1):66. PubMed ID: 31366409
[TBL] [Abstract][Full Text] [Related]
13. Voxelwise Meta-Analysis of Gray Matter Abnormalities in Mild Cognitive Impairment and Subjective Cognitive Decline Using Activation Likelihood Estimation.
Chen S; Xu W; Xue C; Hu G; Ma W; Qi W; Dong L; Lin X; Chen J
J Alzheimers Dis; 2020; 77(4):1495-1512. PubMed ID: 32925061
[TBL] [Abstract][Full Text] [Related]
14. The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study.
Rami L; Mollica MA; García-Sanchez C; Saldaña J; Sanchez B; Sala I; Valls-Pedret C; Castellví M; Olives J; Molinuevo JL
J Alzheimers Dis; 2014; 41(2):453-66. PubMed ID: 24625794
[TBL] [Abstract][Full Text] [Related]
15. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
[TBL] [Abstract][Full Text] [Related]
17. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of Alzheimer's Disease and Cerebrovascular Disease in Relation to Depressive Symptomatology in Individuals With Subjective Cognitive Decline.
Zapater-Fajarí M; Diaz-Galvan P; Cedres N; Rydberg Sterner T; Rydén L; Sacuiu S; Waern M; Zettergren A; Zetterberg H; Blennow K; Kern S; Hidalgo V; Salvador A; Westman E; Skoog I; Ferreira D
J Gerontol A Biol Sci Med Sci; 2024 Feb; 79(2):. PubMed ID: 37708068
[TBL] [Abstract][Full Text] [Related]
20. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
